CRDL Cardiol Therapeutics Inc.

Nasdaq cardiolrx.com


$ 1.06 $ -0.01 (-0.96 %)    

Friday, 17-Oct-2025 19:37:59 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.03
$ 1.03
$ 1.01 x 350
$ 1.11 x 40
$ 1.01 - $ 1.06
$ 0.77 - $ 2.24
723,556
na
85.09M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cardiol-therapeutics-completes-11m-private-placement-selling-11m-units-at-1unit-says-maveric-phase-iii-pivotal-trial-of-orphan-drug-candidate-cardiolrx-in-recurrent-pericarditis-is-fully-funded-through-to-a-planned-nda-submission-with-the-fda-data-from-the-archer-trial-to-be-presented-at-a-cardiology-conference-in-november-2025

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a plan...

 cardiol-therapeutics-reports-compelling-archer-trial-results-supporting-advancement-of-cardiolrx-and-crd-38-in-myocarditis-and-heart-failure

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) fa...

 cardiol-locks-key-trial-data-as-it-advances-new-treatment-for-dangerous-heart-inflammation

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences...

 hc-wainwright--co-initiates-coverage-on-cardiol-therapeutics-with-buy-rating-announces-price-target-of-9

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...

 hc-wainwright--co-initiates-coverage-on-cardiol-therapeutics-with-buy-rating-announces-price-target-of-9

HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Cardiol Therapeutics (NASDAQ:CRDL) with a Buy rating an...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 cardiol-therapeutics-enrolls-first-patient-in-pivotal-phase-iii-maveric-trial-evaluating-cardiolrx-for-prevention-of-recurrent-pericarditis

Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been random...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 cardiol-therapeutics-presents-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis-presented-at-the-aha-scientific-sessions-2024-marked-and-rapid-reductions-in-both-pericarditis-pain-and-inflammation-maintained-throughout-the-26-week-study

Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of peric...

 hc-wainwright--co-reiterates-buy-on-cardiol-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 ...

 why-cardiol-therapeutics-crdl-stock-is-down-20-today

Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering.

 cardiol-therapeutics-announces-pricing-of-135m-public-offering-of-8437500-common-shares-at-a-price-of-160share

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION